$Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: A retrospective study$

Bevacizumab improves overall survival in platinum refractory ovarian cancer patients: A retrospective study

Objective: The objective of this study was to determine the effectiveness of bevacizumab (BV) in combination with chemotherapeutic regimens for prolonging progression-free survival (PFS) as well as overall survival (OS) in patients with platinum-refractory ovarian cancer. Materials and methods: We r...

Full description

Bibliographic Details
Main Authors:	Kenro Chikazawa, Sachiho Netsu, Tomoyuki Kuwata, Ryo Konno
Format:	Article
Language:	English
Published:	Elsevier 2018-12-01
Series:	Taiwanese Journal of Obstetrics & Gynecology
Online Access:	http://www.sciencedirect.com/science/article/pii/S102845591830233X

Similar Items

Myoma morcellation through the navel
by: Kenro Chikazawa, et al.
Published: (2015-02-01)

Nedaplatin use in patients with hypersensitivity reaction episodes to carboplatin
by: Kenro Chikazawa, et al.
Published: (2020-07-01)

Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab
by: Alexandre Sostelly, et al.
Published: (2019-05-01)

Vaginal incision during total laparoscopic hysterectomy may cause severe bradycardia and cardiac arrest
by: Kenro Chikazawa, et al.
Published: (2018-06-01)

Taking care of vesicohypogastric fascia: Enveloping bladder, uterine vessels, and ureter for safe laparoscopic hysterectomy
by: Kenro Chikazawa, et al.
Published: (2020-03-01)

A retrospective analysis of the effect of platinum hypersensitivity reactions on overall survival in patients with epithelial ovarian cancer
by: Young, Jonathan Richard
Published: (2015)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
by: Della Pepa C, et al.
Published: (2014-06-01)

A Retrospective Observational Study of Anlotinib in Patients with Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer
by: Cui Q, et al.
Published: (2021-01-01)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer [Corrigendum]
by: Della Pepa C, et al.
Published: (2014-08-01)

A gauze-tying trocar technique for laparoscopic hysterectomy procedures involving large uteri
by: Ken Imai, et al.
Published: (2019-01-01)

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
by: McClung EC, et al.
Published: (2016-03-01)

Assessing the effectiveness of a weight reduction program in hospitalized obese patients undergoing laparoscopic surgery
by: Ken Imai, et al.
Published: (2021-01-01)

Efficacy and safety of low‐dose apatinib in ovarian cancer patients with platinum‐resistance or platinum‐refractoriness: A single‐center retrospective study
by: Wei Chen, et al.
Published: (2020-08-01)

The impact of delayed reimbursement of bevacizumab on overall survival in patients with metastatic colon cancer
by: Tzu Yu Lin, et al.
Published: (2019)

Huge fetal ovarian cyst
by: Liangcheng Wang, et al.
Published: (2020-04-01)

Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma
by: Jack Patrick Gleeson, et al.
Published: (2020-01-01)

Markers of Oxidative Stress and Inflammation in Ascites and Plasma in Patients with Platinum-Sensitive, Platinum-Resistant, and Platinum-Refractory Epithelial Ovarian Cancer
by: Juan Carlos Cantón-Romero, et al.
Published: (2017-01-01)

Repeating platinum/bevacizumab in recurrent or progressive cervical cancer yields marginal survival benefits
by: Abigail S. Zamorano, et al.
Published: (2017-11-01)

Predictive Factors for RAI-Refractory Disease and Short Overall Survival in PDTC
by: David Kersting, et al.
Published: (2021-04-01)

Bevacizumab and ovarian cancer
by: Agustin Garcia, et al.
Published: (2013-03-01)

Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma
by: Shinichi Tate, et al.
Published: (2021-06-01)

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis
by: Michele Bartoletti, et al.
Published: (2020-05-01)

Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab
by: Anna Krystyna Britton, et al.
Published: (2020-12-01)

Bevacizumab in the therapy for refractory metastatic colorectal cancer
by: Mary F Mulcahy
Published: (2008-03-01)

A Recurrent Platinum Refractory Ovarian Cancer Patient With a Partial Response After RRx-001 Resensitization to Platinum Doublet
by: Hope Cottrill MD, et al.
Published: (2018-03-01)

Bevacizumab in the treatment of ovarian cancer
by: Ramez N Eskander, et al.
Published: (2011-01-01)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
by: Portales Fabienne, et al.
Published: (2009-09-01)

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
by: Francesca Ricci, et al.
Published: (2017-05-01)

Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab
by: J. Gillen, et al.
Published: (2019-11-01)

Evaluation of Pegylated Liposomal Doxorubicin in the Treatment Of Both Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer
by: Hao Lin, et al.
Published: (2004-09-01)

Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report
by: Li A, et al.
Published: (2018-06-01)

Ferroptosis-Related Gene Model to Predict Overall Survival of Ovarian Carcinoma
by: Liuqing Yang, et al.
Published: (2021-01-01)

Identification of Novel lncRNAs in Ovarian Cancer and Their Impact on Overall Survival
by: Nicholas Cardillo, et al.
Published: (2021-01-01)

Detection of Asherman’s syndrome after conservative management of placenta accreta: a case report
by: Kenro Chikazawa, et al.
Published: (2018-11-01)

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
by: Amelia M. Jernigan, et al.
Published: (2013-01-01)

Overall Survival of Ovarian Cancer Patients Is Determined by Expression of Galectins-8 and -9
by: Heiko Schulz, et al.
Published: (2018-01-01)

Does anti-VEGF bevacizumab improve survival in experimental sepsis?
by: Emmanuel Besnier, et al.
Published: (2017-07-01)

Management of Refractory Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia with Bevacizumab
by: Muaaz Masood, et al.
Published: (2021-01-01)

Bevacizumab for Refractory Gastrointestinal Bleeding in Rendu-Osler-Weber Disease
by: Carlos Bernardes, et al.
Published: (2017-10-01)

Efficacy of Bevacizumab combined with EX-PRESS in the treatment of refractory glaucoma
by: Qian Wang
Published: (2018-03-01)